Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2102]

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights...

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )

Shaping the future: advancing HR-NMIBC management beyond BCG

Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas

Shaping the future: advancing HR-NMIBC management beyond BCG ( Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas )

Do all hormone sensitive prostate cancers need triplet therapy?

Dr Deepak Dabkara - Tata Medical Center, Kolkata, India

Do all hormone sensitive prostate cancers need triplet therapy? ( Dr Deepak Dabkara - Tata Medical Center, Kolkata, India )

ESMO 2025: Precision medicine in bladder cancer

Dr Enrique Grande, Prof Syed Hussain, Dr Patrizia Giannatempo, Dr Félix...

ESMO 2025: Precision medicine in bladder cancer ( Dr Enrique Grande, Prof Syed Hussain, Dr Patrizia Giannatempo, Dr Félix Guerrero-Ramos )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

Prof Thomas Powles - Barts Cancer Institute, London, UK

ctDNA-guided adjuvant atezolizumab improves OS in MIBC ( Prof Thomas Powles - Barts Cancer Institute, London, UK )

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only...

Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others ( Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

(Bio) Markers and milestones at the crossroads of mHSPC care 

Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard

(Bio) Markers and milestones at the crossroads of mHSPC care  ( Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard )

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC...

Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC after BCG treatment ( Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

More from ecancer